{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:17:46Z","timestamp":1764911866672,"version":"3.46.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007041","name":"Universidad de Zaragoza","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007041","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To analyze choroidal thickness (CT) in patients with neovascular age-related macular degeneration (nAMD) with type 1 macular neovascularization (MNV) and type 3 (or retinal angiomatous proliferation) after antiVEGF treatment for two years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study enrolling Caucasian na\u00efve patients with nAMD (type 1 MNV), and patients with type 3 MNV with no other ophthalmological disorders, and without switching treatment. Nine manual CT measurements were performed on optical coherence tomography (OCT) Spectralis (Heidelberg Engineering). Demographic data, smoking, disease activity, and number of injections, among others were recorded. Three visits were analyzed: pretreatment baseline visit, first and last visits with no disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      53 eyes of 53 patients with type 1 MNV, and 41 eyes of 41patients with type 3 MNV were analyzed. Both groups received the same number of injections (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.282). Type 3 MNV patients showed lower CT (between 143.29 and 174.17\u03bcm) than type 1 MNV patients (between 169.91 and 220.17\u03bcm) in the baseline visit, but differences disappeared in first and last visits. Choroidal thinning was only observed in type 1 MNV patients between baseline and first visit (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). In the las visit, they had a CT between 87 and 96% of baseline measurement. No other influencing factor was detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with nAMD (type 1 MNV) have higher CT than patients with type 3. However, patients with type 1 MNV experience significant choroidal thinning, and CT is similar in both groups after antiVEGF treatment. Smoking, type of drusen or other OCT features have no influence in this reduction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-025-03840-8","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:25:55Z","timestamp":1764908755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Choroidal changes after antiVEGF in neovascular age-related macular degeneration with type 1 and 3 macular neovascularization"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-6003","authenticated-orcid":false,"given":"Francisco de As\u00eds","family":"Bartol-Puyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"S\u00e1nchez Monroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Puzo Bayod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Mall\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"M\u00e9ndez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Pablo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"10","key":"3840_CR1","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1167\/iovs.10-5196","volume":"51","author":"M Esmaeelpour","year":"2010","unstructured":"Esmaeelpour M, Pova\u017eay B, Hermann B, Hofer B, Kajic V, Kapoor K et al (2010) Three-dimensional 1060-nm OCT: choroidal thickness maps in normal subjects and improved posterior segment visualization in cataract patients. Invest Ophthalmol Vis Sci 51(10):5260\u20135266","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3840_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3567813","author":"FDA Bartol-Puyal","year":"2019","unstructured":"Bartol-Puyal FDA, Isanta C, Ruiz-Moreno \u00d3, Abadia B, Calvo P, Pablo L (2019) Distribution of choroidal thinning in high myopia, diabetes mellitus, and aging: a swept-source OCT study. J Ophthalmol. https:\/\/doi.org\/10.1155\/2019\/3567813","journal-title":"J Ophthalmol"},{"issue":"2","key":"3840_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","volume":"29","author":"DL Nickla","year":"2010","unstructured":"Nickla DL, Wallman J (2010) The multifunctional choroid. Prog Retin Eye Res 29(2):144\u2013168","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"3840_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5301\/ejo.5000675","volume":"26","author":"F Akay","year":"2016","unstructured":"Akay F, Gundogan FC, Yolcu U, Toyran S, Uzun S (2016) Choroidal thickness in systemic arterial hypertension. Eur J Ophthalmol 26(2):152\u2013157","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"3840_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191977","volume":"13","author":"B Abadia","year":"2018","unstructured":"Abadia B, Su\u00f1en I, Calvo P, Bartol F, Verdes G, Ferreras A (2018) Choroidal thickness measured using swept-source optical coherence tomography is reduced in patients with type 2 diabetes. PLoS ONE 13(2):e0191977","journal-title":"PLoS ONE"},{"issue":"5","key":"3840_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ophtha.2010.09.012","volume":"118","author":"SE Chung","year":"2011","unstructured":"Chung SE, Kang SW, Lee JH, Kim YT (2011) Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118(5):840\u2013845","journal-title":"Ophthalmology"},{"issue":"7","key":"3840_CR7","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1097\/IAE.0000000000000086","volume":"34","author":"T Yamazaki","year":"2014","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S (2014) Subfoveal choroidal thickness in retinal angiomatous proliferation. Retina 34(7):1316\u20131322","journal-title":"Retina"},{"issue":"4","key":"3840_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40259-016-0179-0","volume":"30","author":"AM Minnella","year":"2016","unstructured":"Minnella AM, Federici M, Falsini B, Barbano L, Gambini G, Lanza A et al (2016) Choroidal thickness changes after intravitreal ranibizumab for exudative age-related macular degeneration. BioDrugs 30(4):353\u2013359","journal-title":"BioDrugs"},{"issue":"8","key":"3840_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S (2012) Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119(8):1621\u20131627","journal-title":"Ophthalmology"},{"issue":"3","key":"3840_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T et al (2016) Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology 123(3):617\u2013624","journal-title":"Ophthalmology"},{"issue":"8","key":"3840_CR11","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1097\/IAE.0000000000000952","volume":"36","author":"YK Kim","year":"2016","unstructured":"Kim YK, Park SJ, Woo SJ, Park KH (2016) Choroidal thickness change after intravitreal anti-vascular endothelial growth factor treatment in retinal angiomatous proliferation and its recurrence. Retina 36(8):1516\u20131526","journal-title":"Retina"},{"issue":"4","key":"3840_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/IAE.0000000000000486","volume":"35","author":"I Maruko","year":"2015","unstructured":"Maruko I, Iida T, Oyamada H, Sugano Y, Saito M, Sekiryu T (2015) Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Retina 35(4):648\u2013654","journal-title":"Retina"},{"issue":"4","key":"3840_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000488254","volume":"240","author":"TCM Kanadani","year":"2018","unstructured":"Kanadani TCM, Veloso CE, Nehemy MB (2018) Subfoveal choroidal thickness in eyes with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents. Ophthalmologica 240(4):200\u2013207","journal-title":"Ophthalmologica"},{"issue":"4","key":"3840_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00417-018-04216-8","volume":"257","author":"V Bouteleux","year":"2019","unstructured":"Bouteleux V, Kodjikian L, Mendes M, Agard E, Machkour-Bentaleb Z, El-Chehab H et al (2019) Increased choroidal thickness: a new feature to monitor age-related macular degeneration recurrence. Graefes Arch Clin Exp Ophthalmol 257(4):699\u2013707","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"3840_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/IAE.0000000000002845","volume":"41","author":"JY Park","year":"2021","unstructured":"Park JY, Kang MJ, Kim BG, Chung KH, Sim HE, Lee SW et al (2021) Topographic changes in choroidal thickness in age-related macular degeneration during the development of active choroidal neovascularization. Retina 41(2):409\u2013422","journal-title":"Retina"},{"issue":"3","key":"3840_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00417-017-3888-2","volume":"256","author":"W Fan","year":"2018","unstructured":"Fan W, Abdelfattah NS, Uji A, Lei J, Ip M, Sadda SVR et al (2018) Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefes Arch Clin Exp Ophthalmol 256(3):511\u2013518","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"3840_CR17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1167\/iovs.11-8836","volume":"53","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Yamashita T, Shirasawa M, Arimura N, Terasaki H, Sakamoto T (2012) Repeatability and reproducibility of subfoveal choroidal thickness in normal eyes of Japanese using different SD-OCT devices. Invest Ophthalmol Vis Sci 53(3):1102\u20131107","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"3840_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/IAE.0000000000002022","volume":"9","author":"B Abad\u00eda","year":"2018","unstructured":"Abad\u00eda B, Calvo P, Bartol-Puyal F, Verdes G, Su\u00f1\u00e9n I, Ferreras A (2018) Repeatability of choroidal thickness measurements assessed with swept-source optical coherence tomography in healthy and diabetic individuals. Retina 9(4):786\u2013793","journal-title":"Retina"},{"issue":"10","key":"3840_CR19","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","volume":"261","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H (2023) Short-term outcomes of intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 261(10):2945\u20132952","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"3840_CR20","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","volume":"260","author":"T Tamashiro","year":"2022","unstructured":"Tamashiro T, Tanaka K, Itagaki K, Nakayama M, Maruko I, Wakugawa S et al (2022) Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol 260(6):1857\u20131865","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3840_CR21","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.12.7.12","author":"J Reche","year":"2023","unstructured":"Reche J, Stocker AB, Henchoz V, Habra O, Escher P, Wolf S et al (2023) High-resolution optical coherence tomography in healthy individuals provides resolution at the cellular and subcellular levels. Transl Vis Sci Technol. https:\/\/doi.org\/10.1167\/tvst.12.7.12","journal-title":"Transl Vis Sci Technol"},{"key":"3840_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ajo.2015.12.024","volume":"164","author":"DSW Ting","year":"2016","unstructured":"Ting DSW, Ng WY, Ng SR, Tan SP, Yeo IYS, Mathur R et al (2016) Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Am J Ophthalmol 164:128\u201336.e1","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3840_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00417-023-06278-9","volume":"262","author":"AD Abdin","year":"2024","unstructured":"Abdin AD, Hanifa O, Aljundi W, Munteanu C, Seitz B, Suffo S (2024) Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up). Graefes Arch Clin Exp Ophthalmol 262(2):457\u2013468","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"3840_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ajo.2015.08.009","volume":"160","author":"S Razavi","year":"2015","unstructured":"Razavi S, Souied EH, Darvizeh F, Querques G (2015) Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol 160(5):1006\u20131013","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"3840_CR25","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1097\/IAE.0000000000001480","volume":"37","author":"S Palkovits","year":"2017","unstructured":"Palkovits S, Seidel G, Pertl L, Malle EM, Hausberger S, Makk J et al (2017) Macular choroidal volume changes after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 37(12):2262\u20132268","journal-title":"Retina"},{"issue":"2","key":"3840_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10384-021-00894-w","volume":"66","author":"O Altunel","year":"2022","unstructured":"Altunel O, Ozsaygili C (2022) Assessment of choriocapillaris\/Sattler and Haller layer changes after intravitreal injection in eyes with neovascular age-related macular degeneration: aflibercept vs ranibizumab. Jpn J Ophthalmol 66(2):159\u2013166","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"3840_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R et al (2015) Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 159(4):627\u201333.e1","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"3840_CR28","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-306636","volume":"99","author":"K Mazaraki","year":"2015","unstructured":"Mazaraki K, Fassnacht-Riederle H, Blum R, Becker M, Michels S (2015) Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration. Br J Ophthalmol 99(10):1341\u20131344","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"3840_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.5301\/ejo.5000509","volume":"24","author":"EC McDonnell","year":"2014","unstructured":"McDonnell EC, Heussen FM, Ruiz-Garcia H, Ouyang Y, Narala R, Walsh AC et al (2014) Effect of anti-VEGF treatment on choroidal thickness over time in patients with neovascular age-related macular degeneration. Eur J Ophthalmol 24(6):897\u2013903","journal-title":"Eur J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03840-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03840-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03840-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:25:56Z","timestamp":1764908756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03840-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3840"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03840-8","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"8"}}